Intratumoral delivery of TransCon ™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction.
Luis Alejandro ZúñigaTorben LeßmannKaran UppalNicola BisekEnping HongCaroline E RasmussenJens-Jakob KarlssonJoachim ZettlerLars Holten-AndersenKathy BangDhruv ThakarYu-Chi LeeSalomon MartinezSimran Singh SabharwalSebastian StarkFrank FaltingerOliver KrackerSamuel WeisbrodRobin MüllerTobias VoigtKornelia BigottMohammad TabrizifardVibeke Miller BreinholtAmer M MirzaDavid B RosenKennett SprogøeJuha PunnonenPublished in: Cancer cell international (2022)
Our findings show that a single dose of TransCon TLR7/8 Agonist can mediate sustained local release of resiquimod in the TME and promote potent anti-tumor effects as monotherapy and in combination with systemic immunotherapy, supporting TransCon TLR7/8 Agonist as a novel intratumoral TLR agonist for cancer therapy. A clinical trial to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, as monotherapy and in combination with pembrolizumab, in cancer patients is currently ongoing (transcendIT-101; NCT04799054).